James Gordon
Stock Analyst at Barclays
(2.58)
# 2,142
Out of 5,147 analysts
11
Total ratings
66.67%
Success rate
16.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Gordon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GSK GSK plc | Downgrades: Underweight | n/a | $59.13 | - | 1 | Jan 6, 2026 | |
| ARGX argenx SE | Maintains: Overweight | $925 → $1,100 | $766.92 | +43.43% | 8 | Dec 8, 2025 | |
| GRFS Grifols | Maintains: Neutral | $7.6 → $10 | $9.10 | +13.19% | 1 | Jun 17, 2025 | |
| GMAB Genmab | Downgrades: Neutral | n/a | $29.44 | - | 1 | Aug 20, 2024 |
GSK plc
Jan 6, 2026
Downgrades: Underweight
Price Target: n/a
Current: $59.13
Upside: -
argenx SE
Dec 8, 2025
Maintains: Overweight
Price Target: $925 → $1,100
Current: $766.92
Upside: +43.43%
Grifols
Jun 17, 2025
Maintains: Neutral
Price Target: $7.6 → $10
Current: $9.10
Upside: +13.19%
Genmab
Aug 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $29.44
Upside: -